Anti-Human Beta Site APP Cleaving Enzyme (CT) (BACE)

PN:B365

This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.

This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.

Next Day Ambient

Rabbit Anti-Human Beta Site APP Cleaving Enzyme (BACE) recognizes recognizes an epitope near the C-terminus of Human and Mouse BACE. This polyclonal antibody was purified using affinity chromatography.

Accumulation of the amyloid-b (Ab) plaque in the cerebral cortex is a critical event in the pathogenesis of Alzheimer’s disease. Ab peptide is generated by proteolytic cleavage of the b-amyloid protein precursor (APP) at b- and g-sites by two proteases. APP is first cleaved by b-secretase, producing a soluble derivative of the protein and a membrane anchored 99-amino acid carboxy-terminal fragment (C99). The C99 fragment serves as substrate for g-secretase to generate the 4 kDa amyloid-b peptide, which is deposited in the brains of all suffers of Alzheimer’s disease. The long-sought b-secretase was recently identified by several groups independently and designated β-site APP cleaving enzyme (BACE) and aspartyl protease 2 (Asp2).^1-4 BACE/Asp2 is a novel transmembrane aspartic protease and colocalizes with APP.

1. Vassar, R. et al. (1999) Science 286:735 2. Hussain, I. et al. (1999) Mol. Cell Neurosci. 14:419 3. Yan, R. et al. (1999) Nature 402:533 4. Sinha, S. et al. (1999) Nature 402:537